A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial.

Objectives. Rivaroxaban 2.5 mg twice daily with aspirin 100 mg daily was superior to aspirin 100 mg daily in the COMPASS trial but the cost-effectiveness in Scandinavia is unknown. Design. Mean lifetime costs (USDs) and quality-adjusted life-years were determined from a Scandinavian perspective using a 2-state Markov model with US mortality data. Subgroup and sensitivity analyses were performed. Results. Over a lifetime adding rivaroxaban to aspirin had lower costs (-$3791USD/-23675DKK/-27410NOK/-29200SEK) and gained 1.17 QALYs versus ASA alone. Conclusion. Rivaroxaban 2.5 mg twice daily with aspirin is a dominant strategy compared to aspirin alone in COMPASS participants from a Scandinavian perspective.